Search Videos and More
News
Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)
Pivotal phase III VERONA trial results presented at the American Society of Hematology annual meeting show no overall survival improvement, but potential for sub-group benefit and no added side effects.
News
Sickle-cell disease associated with early onset of clonal hematopoiesis, a precancerous condition
The discovery, led by researchers at Dana-Farber, could pave the way for interventions to reduce the risk of blood cancers among people with sickle-cell disease.
News
Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium
Physician scientists from Dana-Farber Cancer Institute will present more than 50 research studies at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.
Document
Treatment Guideline: Inavolisib, Palbociclib, and Fulvestrant for Hormone Receptor-Positive/HER2-negative Metastatic Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held meetings to discuss recommendations regarding the use of inavolisib, palbociclib, and fulvestrant in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
News
Ensuring the Future of Innovation
Dana-Farber empowers early-career investigators to accelerate breakthroughs and build the next generation of innovators in cancer treatment
News
Dana-Farber Research News 12.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 - 15.
Symposium
San Antonio Breast Cancer Symposium 2025
Dana-Farber Cancer Institute Faculty highlights from the 2025 San Antonio Breast Cancer Symposium.
Video
ESMO25 Breast Cancer Highlights
Harold Burstein, MD, PhD, and other breast cancer experts at Dana-Farber discuss important breast cancer research presented at ESMO 2025.
Video
ESMO25 Breast Cancer Highlights: Antibody-Drug Conjugates
Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss OptiTROP-Breast02 and other trials investigating antibody-drug conjugates (ADCs).
Video
ESMO25 Breast Cancer Highlights: ASCENT-03 and TROPION-Breast02
Harold Burstein, MD, PhD, and Ana Garrido-Castro, MD, discuss the ASCENT-03 and TROPION-Breast02 trials, investigating antibody-drug conjugates for triple-negative breast cancer.
Video
ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05
Harold Burstein, MD, PhD, and Guilherme Nader-Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials examining trastuzumab deruxtecan in HER2-positive breast cancer.
Video
ESMO25 Breast Cancer Highlight Recap
Harold Burstein, MD, PhD, summarizes important breakthroughs presented at ESMO 2025 for all sub-types and stages of breast cancer.